Definitive Healthcare Posts Q2 Revenue of $55.2M, Sets Q3 Guidance at $54–$55M

summarizeSummary

Definitive Healthcare reported Q2 2026 revenue of $55.2 million, down 9% YoY, alongside adjusted EBITDA of $14.6 million. The company guided Q3 revenue to $54–$55 million and full-year revenue to $220–$222 million, reflecting ongoing top-line pressure but steady profitability.

check_boxKey Events · Earnings and Guidance · DH

• Q2 Revenue In Line, Profit Beats

  Revenue of $55.2 million was within guidance, while adjusted EBITDA of $14.6 million (26% margin) exceeded expectations. Net loss narrowed to $(7.5) million from $(9.3) million a year ago.

• Revenue Decline Continues

  Revenue fell 9% year-over-year, consistent with recent trends. The company cited improving net dollar retention and customer win-backs as early signs of stabilization.

• Q3 and Full-Year Guidance Issued

  Q3 revenue is expected to be $54.0–$55.0 million with adjusted EBITDA of $13.5–$14.5 million. Full-year 2026 revenue guidance of $220–$222 million implies a continued decline from 2025 levels.

• AI Platform Launch

  The company launched Turbo, a new AI-powered healthcare intelligence platform, which management called a significant milestone in its innovation strategy.

auto_awesomeAnalysis · DH · Technology

Definitive Healthcare's Q2 revenue landed within its guided range, while profitability topped expectations—adjusted EBITDA reached $14.6 million, a 26% margin. Although the top line contracted 9% year-over-year, the company pointed to a second straight quarter of improving net dollar retention and a strong pace of customer win-backs as encouraging signals. A notable product milestone came with the launch of Turbo, an AI-powered platform. Looking ahead, Q3 and full-year 2026 guidance points to further revenue declines but steady margins. Set against a recent Nasdaq delisting notice and a massive goodwill impairment earlier this year, these results suggest operational stabilization, though a return to growth remains elusive.